Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluarix 2007/2008 Immunogenicity and Reactogenicity Study
NCT00476307Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2007
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Fluarix in influenza, sponsored by GSK. Primary endpoint: Immune response at 21 days. Started Jun 2007; status: completed.
02
Drugs
Fluarix
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00476307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00476307.